Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.
An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.
In this Blood Spotlight, Huls et al highlight why small molecule inhibitors of menin are creating excitement in the acute myeloid leukemia (AML) field with
The NIH said capping indirect cost payments will save billions of dollars. Universities said it will disrupt vital, life-saving research.
Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.
Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.
In this issue of Blood, Luskin et al present results of the first phase 1 trial combining asciminib, an allosteric BCR::ABL1 inhibitor, with the tyrosine k
David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.
An abstract is unavailable.
